Introduction {#Sec1}
============

Gastric cancer is one of the most common malignant diseases worldwide; the incidence and mortality for GC is still high \[[@CR1]\]. Surgical resection with lymph node dissection is the most effective treatment for gastric cancer \[[@CR2]\]. In the past, conventional open gastrectomy (OG) has been the mainstay of treatment for gastric cancer. Since laparoscopy-assisted gastrectomy was first described in 1994 \[[@CR3]\], endoscopic and laparoscopic procedures for early gastric cancer have been increasingly used because of many advantages over OG, including less blood loss, fewer postoperative complications, faster bowel function recovery, shorter hospital stay, and an equivalent long-term outcomes \[[@CR4]--[@CR6]\]. The application of laparoscopic gastrectomy (LG) for advanced gastric cancer (AGC) was first reported \[[@CR7]\]. Although several clinical trials have reported the effectiveness of LG \[[@CR8], [@CR9]\], considering of lacking of long-term oncological outcomes and the technical difficulties, there is no enough evidence to support LG for treating AGC; thus, the use of LG for AGC has been still controversial. Many previous meta-analyses have compared the short-term postoperative outcomes and long-term outcomes \[[@CR10], [@CR11]\], whereas they have analyzed the results without enough clinical randomized trials and/or with low-quality studies. Many high-quality RCTs related with LG treating AGC have been published recently, especially between 2018 and 2019. Therefore, we conducted this systematic review and meta-analysis to find some proofs for the use of LG in AGC.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

The comprehensive publications were identified by searching medical electronic databases PubMed, EMBASE, and Web of Science, which published from July 2010 to May 2019. The following MeSH terms and free-text terms were used: "laparoscopy-assisted gastrectomy", "laparoscopic-assisted gastrectomy", "laparoscopy surgery", "laparoscopies", "laparoscopic surgery", "open gastrectomy", "conventional gastrectomy", "stomach neoplasms", "gastric cancer", "gastric neoplasm", and "stomach cancer"; the Boolean operators "AND" and "OR" were used to combined these terms. The references of the relevant articles and previous meta-analysis studies were identified as additional articles. Title and abstracts of each identified article were screened, and the full text of the screened articles was assessed for eligibility. Three authors researched and reviewed independently and thoroughly through the above-mentioned search strategy; the search strategy was provided as supplementary file.

Criteria of inclusion and exclusion {#Sec4}
-----------------------------------

All included publications in this meta-analysis should meet following criteria: Clinical studies containing RCTs and NRCTs (case-control study, and cohort study)Clinical studies having compared LG versus OG for treatment of advanced gastric cancerDetailed/available data of clinical studies have been reported, including short- or long-term dataPublication in English

All papers containing any of the following criteria were excluded: Duplicate publication or the publication that did not provide sufficient dataNo OG as a control groupRobot-assisted gastrectomyAbstract onlyGastric surgery performed on benign lesions, non-primary gastric cancer, or recurrent gastric cancerPatients in publication had non-curative factors such as distant metastasis of organs

Data extraction {#Sec5}
---------------

Clinical data was extracted independently and evaluated critically by two authors. Relevant data included characteristics of included study (author, year of publication, country of publication, study design, study period, male/female, age, tumor size, BMI, ASA (1:2:3)); summary of laparoscopic technique of included study (type of dissection, type of gastrectomy, retrieved LN, proximal margin, distal margin); systematic review of OS outcomes (follow-up (months), 5-y OS with relevant *P*); systematic review of recurrence pattern and sites; surgical outcomes including operative time, intraoperative blood loss, and harvested lymph nodes; recovery outcomes including time to first flatus, time to first oral intake, hospital stay, and mortality (defined as 30-day operative mortality); long-term outcomes including tumor recurrence and 5-year OS; and postoperative complications were classified as morbidity, overall complications, specific complications, and general complications. General complications included pneumonia, wound problems, postoperative ileus, and pancreatitis or pancreatic leakage; specific complications included intra-abdominal bleeding, anastomotic bleed, anastomotic stenosis, anastomotic leakage, duodenal stump leakage, abdominal infection, and lymphatic fistula.

Quality assessment {#Sec6}
------------------

To assess the quality of included studies, we used the Newcastle-Ottawa Quality Assessment Scale (NOS) for non-RCT \[[@CR12]\]. NOS contains 3 categories including selection, comparability, and outcome, which were scaled by eight elements; high-quality elements are awarded by adding a star, no more than one stars could be added into the elements of selection and outcome, and no more than two stars could be added into the elements of comparability; then, studies were compared according to the number of stars, total score was 9 stars, 0--5 stars was considered as low-quality and 6--9 stars was considered as high quality. The risk of bias and quality of RCTs were determined by the Jadad scale (JCS) \[[@CR13]\]. The high-quality trials should score ≥ 3 of a maximum possible score of 5.

Statistical analysis {#Sec7}
--------------------

STATA 12.0 for Windows was performed for this study. Dichotomous data was calculated by relative risks (RR) with 95% confidence intervals, and continuous variables were calculated by weighted mean differences (WMD) with 95% (CI); 5-year OS was evaluated by pooled hazard ratios (HR) and their 95% CI. When the HR and 95% CI were not provided in the studies, some published formula were performed to calculate HR with 95% Cl \[[@CR14]\]. A random effect model was used for studies with high heterogeneity, while a fixed-effect model was used for low heterogeneity. *χ*^2^ test was used to assess heterogeneity. Funnel plots and Egger's linear regression test were used to assess the publication bias. *P* ≤ 0.05 was considered to indicate statistical significance.

Result {#Sec8}
======

Results of the search and quality assessment {#Sec9}
--------------------------------------------

The study selection process is summarized in the flowchart (Fig. [1](#Fig1){ref-type="fig"}). A total of 1220 publications were researched according to the search strategy, eighteen articles were excluded after duplication, and after titles, abstracts, and language were retrieved to assess further, 1140 publications were excluded. Of these studies, twenty-six studies were excluded because they included early gastric cancer only or almost early gastric cancer, were protocols of ongoing studies, were review, and were no control group. In the end, eighteen case-control studies, ten cohort studies, and eight RCT were enrolled in the studies \[[@CR15]--[@CR49]\]. In terms of non-RCT studies, four studies scored 6 (moderate-quality study) on the NOS, and twenty-four studies scored 8--9 (high-quality study) (Table [1](#Tab1){ref-type="table"}). With regard to RCT, two studies scored 4 (high-quality study) on the JCS, and six studies scored 2 (moderate-quality) (Table [2](#Tab2){ref-type="table"}). Fig. 1Flow diagram of the meta-analysisTable 1Assessment of quality of non-RCT studies (NOS)ReferencesSelectionComparabilityOutcomeYearRECSNECAEDOSCAFAOFUFUOScoreZhang et al. \[[@CR40]\]2017\*\*\*\*\*\*\*\*8Xu1 et al. \[[@CR39]\]2017\*\*\*\*\*\*\*\*\*9Lu et al. \[[@CR37]\]2016\*\*\*\*\*\*\*\*\*9Hao et al. \[[@CR33]\]2016\*\*\*\*\*\*\*\*8Zhang et al. \[[@CR32]\]2015\*\*\*\*\*\*\*\*8Wu et al. \[[@CR31]\]2015\*\*\*\*\*\*6Gordon et al. \[[@CR25]\]2013\*\*\*\*\*\*\*\*8Bo et al. \[[@CR24]\]2013\*\*\*\*\*\*\*\*\*9Chun et al. \[[@CR20]\]2012\*\*\*\*\*\*\*\*8Chen et al. \[[@CR19]\]2012\*\*\*\*\*\*\*\*\*9Zhao et al. \[[@CR18]\]2011\*\*\*\*\*\*\*\*8Shuang et al. \[[@CR17]\]2011\*\*\*\*\*\*\*\*8Shinohara et al. \[[@CR27]\]2013\*\*\*\*\*\*\*\*\*9Li3 et al. \[[@CR42]\]2018\*\*\*\*\*\*\*\*\*9Chan et al. \[[@CR45]\]2019\*\*\*\*\*\*\*\*\*9Fang et al. \[[@CR28]\]2014\*\*\*\*\*\*\*\*\*9Xu2 et al. \[[@CR49]\]2018\*\*\*\*\*\*\*\*\*9Huang et al. \[[@CR14]\]2010\*\*\*\*\*\*6Hamabe et al. \[[@CR21]\]2012\*\*\*\*\*\*\*\*\*9Scatizzi et al. \[[@CR16]\]2011\*\*\*\*\*\*\*\*8Inokuchi et al. \[[@CR41]\]2018\*\*\*\*\*\*\*\*\*9Li^1^ et al. \[[@CR35]\]2016\*\*\*\*\*\*6Zhang et al. \[[@CR38]\]2016\*\*\*\*\*\*\*\*\*9Kinoshita et al. \[[@CR46]\]2019\*\*\*\*\*\*\*\*\*9Kim et al. \[[@CR22]\]2012\*\*\*\*\*\*\*\*8Moisan et al. \[[@CR23]\]2012\*\*\*\*\*\*\*\*8Qiu et al. \[[@CR29]\]2014\*\*\*\*\*\*6Lin et al. \[[@CR26]\]2013\*\*\*\*\*\*\*\*\*9*REC* representativeness of the exposed cohort, *SNEC* selection of the non-exposed cohort, *AE* ascertainment of exposure, *DO* demonstration that outcome of interest was not present at start of study, *SC* study controls for age and sex, *AF* study controls for any additional factors, *AO* assessment of outcome, *FU* follow-up long enough for outcomes to occur, *FUO* adequacy of follow-up of cohortsTable 2Assessment of quality of RCTs (Jadad scale)ReferencesYearRandomizationBlindingWithdraw and dropoutJadad's scoreWang et al. \[[@CR48]\]20192002Lee et al. \[[@CR47]\]20192002Shi et al. \[[@CR44]\]20182002Park et al. \[[@CR43]\]20182024Li1 et al. \[[@CR35]\]20162002Hu et al. \[[@CR34]\]20162024Cai et al. \[[@CR15]\]20111011Cui et al. \[[@CR30]\]20152002Randomization: randomization was described with appropriate method---2 score, randomization was described without appropriate method---1 score, no randomization---0 score. Blinding: blinding was performed on all doctors and patients---2 score, blinding was partially performed on doctors and patients---1 score, no blinding---0 score. Withdraw and dropout: the reason of withdraw and dropout was described---1 score, the reason of withdraw and dropout was not described---0 score. Quality: high-quality trials should score ≥ 3, moderate-quality trials should score ≥ 2

Characteristics of included study {#Sec10}
---------------------------------

According to the search strategy and criteria of inclusion and exclusion, a total of thirty-six studies published from 2010 to 2019 were eligible for the meta-analysis. A total of 11,808 cases (5714 cases in LAG and 6094 cases in OG) were involved in the study. Among the thirty-six studies, twenty-five studies originated from China, five originated from Japan, four originated from Korea, one originated from Italy, and one originated from Chile. Detailed information for characteristics of included study is shown in Table [3](#Tab3){ref-type="table"}. Table 3Characteristics of included studiesReferencesYearCountryStudy designStudy periodMale/femaleAgeTumor sizeBMIASA (1:2:3)LOLOLOLOHuang et al. \[[@CR14]\]2010Chi-Cohort2007--200840/2639/3055.80 ± 9.2156.37 ± 10.63-----Cai et al \[[@CR15]\]2011Chi-RCT2008--200939/1037/1054.4 ± 10.652.6 ± 13.64.15 ± 2.034.32 ± 1.7821.99 ± 3.2922.87 ± 2.76--Scatizzi et al. \[[@CR16]\]2011ItalyCCS2006--200914/1616/1470 ± 1269 ± 10.755.6 ± 37.2 ± 2.2522 ± 124 ± 6.58/25/17Shuang et al \[[@CR17]\]2011Chi-CCS2005--200730/530/558 ± 10.559 ± 16--21 ± 323 ± 3--Zhao et al. \[[@CR18]\]2011Chi-CCS2004--2009248/98221/9251.43 ± 11.4552.57 ± 12.374.4 ± 1.574.6 ± 1.72----Chun et al. \[[@CR20]\]2012KoreaCCS2004--200930/2248/1961.1 ± 12.660.8 ± 11.13.4 ± 1.64.0 ± 2.122.8 ± 2.822.9 ± 3.0--Hamabe et al. \[[@CR21]\]2012JapanCohort2000--200947/1970/3166.364.23.544.05----Kim et al. \[[@CR22]\]2012KoreaCCS2006--200753/3550/3856.0 ± 13.559.0 ± 13.13.8 ± 2.25.2 ± 2.722.9 ± 3.022.5 ± 3.0--Moisan et al. \[[@CR23]\]2012ChileCohort2003--201021/1020/1167 ± 13.567 ± 143.7 ± 1.9754.5 ± 2.42526 ± 2.7525.5 ± 3.522/38/2Bo et al. \[[@CR24]\]2013Chi-CCS2004--201082/3580/3754.5 ± 10.652.6 ± 13.6--21.1 ± 3.021.7 ± 3.8--Gordon et al. \[[@CR25]\]2012JapanCCS1999--201018/4839/9363.95 ± 12.1166.96 ± 11.86--22.84 ± 3.4522.06 ± 3.33--Lin et al. \[[@CR26]\]2013Chi-Cohort2008--201012/7112/7161.6 ± 10.361.1 ± 10.54.6 ± 2.14.4 ± 2.222.321.5--Shinohara et al. \[[@CR27]\]2012JapanCohort1998--2008129/5785/3861.4 ± 11.763.1 ± 9.9--21.5 ± 3.221.4 ± 3.3173/127/9Fang et al. \[[@CR28]\]2014Chi-CCS2005--200978/978/957 ± 8.1656 ± 7.664.4 ± 1.904.8 ± 1.5023.3 ± 2.21622.9 ± 2.21669/81/24Qiu et al. \[[@CR29]\]2014Chi-CCS2012--201325/522/1274.4 ± 3.175.6 ± 3.04.1 ± 1.94.9 ± 2.621.6 ± 2.721.6 ± 3.02/45/17Cui et al. \[[@CR30]\]2015Chi-RCT2010--201288/4098/4460.1 ± 12.657.5 ± 11.2--23.03 ± 3.6123.66 ± 3.23--Wu et al. \[[@CR31]\]2015Chi-CCS2010--201292/68115/8058.09 ± 10.8758.61 ± 12.33--22.40 ± 3.8522.20 ± 3.75--Zhang et al. \[[@CR32]\]2015Chi-CCS2007--201457/2961/2562 ± 4.8361 ± 4.00----107/49/16Hao et al. \[[@CR33]\]2016Chi-CCS2004--2011437/191414/16554.57 ± 14.4655.66 ± 12.59----610/520/77Hu et al. \[[@CR34]\]2016Chi-RCT2012--2014380/129346/17456.5 ± 10.455.8 ± 11.14.0 ± 2.04.0 ± 2.122.7 ± 3.222.7 ± 3.2--Li1 et al. \[[@CR35]\]2016Chi-CCS2012--201454/4753/4857.7 ± 10.559.5 ± 10.1--23.7 ± 71.123.7 ± 1.057/106/39Li2 et al. \[[@CR35]\]2016Chi-RCT2012--201413/727/353.5 ± 9.256.0 ± 9.23.7 ± 1.92.5 ± 1.322.4 ± 3.723.0 ± 3.11/38/5Lu et al. \[[@CR37]\]2016Chi-CCS2008--201539/2237/2459 ± 7.7557 ± 6.75--19 ± 1.2522 ± 288/26/8Zhang et al. \[[@CR38]\]2016Chi-CCS2009--201465/2759/3363 ± 5.6665 ± 5.66--19 ± 1.6622 ± 1.33120/47/17Xu1 et al. \[[@CR39]\]2017Chi-CCS2007--201160/760/758.5 ± 10.557.7 ± 9.65.4 ± 2.35.8 ± 2.222.5 ± 3.222.6 ± 3.55/105/24Zhang et al. \[[@CR40]\]2017Chi-Cohort2006--200863/4869/5057.2 ± 11.258.7 ± 12.1------Inokuchi et al. \[[@CR41]\]2018JapanCCS2001--201239/1337/1567 ± 10.2568 ± 13--21.9 ± 3.6522.1 ± 3.17539/52/13Li3 et al. \[[@CR42]\]2018Chi-Cohort2007--2012322/88311/99--------Park et al. \[[@CR43]\]2018KoreaRCT2010--201169/3165/3158.660.1--23.7 ± 3.023.3 ± 3.1--Shi et al. \[[@CR44]\]2018Chi-RCT2010--2012120/42105/5555.23 ± 11.0155.02 ± 10.794.28 ± 1.944.40 ± 1.9720.7 ± 3.08620.2 ± 2.948161/128/33Xu2 et al. \[[@CR49]\]2018Chi-Cohort2005--2012342/88595/17355.6 ± 10.456.8 ± 10.64.7 ± 1.84.9 ± 1.822.4 ± 3.022.2 ± 3.2165/873/157Chan et al. \[[@CR45]\]2019Hong KongCohort2009--201735/19110/5770 ± 12.566 ± 9.5----13/136/71Chen et al. \[[@CR19]\]2012Chi-CCS2008--201049/17523/8961.6 ± 10.660.8 ± 10.24.7 ± 2.04.4 ± 2.022.322180/143/13Kinoshita et al. \[[@CR46]\]2019JapanCohort2008--2014214/91217/8867.167.7--21.5 ± 3.121.6 ± 3.4195/359/56Lee et al. \[[@CR47]\]2019KoreaRCT2011--2015333/127321/13759.9 ± 10.859.5 ± 11.64.5 ± 2.44.5 ± 2.223.5 ± 2.923.7 ± 2.3445/431/42Wang et al. \[[@CR48]\]2019Chi-RCT2014--2017144/78133/8759.4 ± 12.660.6 ± 10.23.6 ± 1.83.9 ± 1.223.1 ± 3.123.5 ± 3.5179/255/8*RCT* randomized controlled trial, *CCS* case-controlled study, *L* laparoscopic gastrectomy, *O* open gastrectomy, *TG* total gastrectomy, *DG* distal gastrectomy, *PG* proximal gastrectomy, *--* not available

Summary of laparoscopic technique {#Sec11}
---------------------------------

All the included studies have reported the laparoscopic technique. Thirty-four studies have demonstrated the details on the level of lymphadenectomy, D2 lymphadenectomy was performed in 29 studies, D1, D1+, D2, and D2 + lymphadenectomy were used in three studies, D1 + α/β and D2 were used in one study, and D0, D1, D1 + α/β, D2, and D2+ were performed in one study. All the studies have reported the type of gastrectomy; compared with proximal and subtotal gastrectomy, distal and total gastrectomy were frequently used for advanced gastric cancer. Twelve studies reported the resection margin in both LADG and ODG groups, only one article showed there was significant difference in proximal margin between the two groups \[[@CR21]\], and all the rest indicated no significant difference between the two groups for proximal margin and distal margins. Thirty-five studies have shown detailed data of retrieved LN between the two groups, thirty-two studies indicated no significant difference, while three studies showed *P* \< 0.05. Detailed information for characteristics of included studies is shown in Table [4](#Tab4){ref-type="table"}. Relevant pathological characteristics of included studies are shown in Table [5](#Tab5){ref-type="table"}. Table 4Summary of laparoscopic techniqueReferenceType of dissectionType of gastrectomyRetrieved LNProximal marginDistal marginLOPLOPLOPHuang et al. \[[@CR14]\]D2DG25.81 ± 12.5327.47 ± 0.280.401\--Zhao et al. \[[@CR18]\]D1,D1 + α, β, D2, D2+DG33.2 ± 12.532.8 ± 15.60.7156.25 ± 2.046.29 ± 2.110.8055.68 ± 1.715.62 ± 1.590.642Shuang et al. \[[@CR17]\]D2DG35 (7--63)38 (6--66)NS----Scatizzi et al. \[[@CR16]\]D2DG37 (8--89)31 (16--60)0.174----Cai et al. \[[@CR15]\]D2PG DG TG22.98 ± 2.70422.8 ± 2.4280.839----Chun et al. \[[@CR20]\]D2DG39.1 ± 15.239.3 ± 11.20.9715.0 ± 2.96.0 ± 3.60.0146.0 ± 3.45.4 ± 3.10.372Chen et al. \[[@CR19]\]D2DG TG30.6 ± 10.130.3 ± 8.60.786----Hamabe et al. \[[@CR21]\]D2DG TG63.7 ± 26.444.0 ± 18.9\< 0.0001----Kim et al. \[[@CR22]\]D2TG SG TG38.3 ± 14.341.8 ± 15.30.11874.4 ± 3.04.5 ± 3.10.86957.3 ± 4.87.2 ± 5.40.9363Moisan et al. \[[@CR23]\]D1 + α, D1 + β, D2TG SG35 (9--68)39 (12--109)0.805--5.5 (0.3--13.5)5.5 (0.3--13.5)0.982Gordon et al. \[[@CR25]\]D0, D1, D1 + α, D1 + β, D2, D2+DG35.92 ± 12.6036.5 ± 14.480.739----Bo et al. \[[@CR24]\]--TG35.2 ± 11.737.4 ± 13.20.1323.5 ± 1.23.2 ± 0.90.517--Shinohara et al. \[[@CR27]\]D2DG PG TG45.3 ± 16.943.8 ± 17.20.446----Lin et al. \[[@CR26]\]D2TG DG30.2 ± 10.128.0 ± 8.10.103----Fang et al. \[[@CR28]\]D2TG DG32 (8--65)36 (12--72)NS----Qiu et al. \[[@CR29]\]D2DG TG30.2 ± 12.028.1 ± 11.80.484----Zhang et al. \[[@CR32]\]D2DG TG20 (16--23)21 (17--23)0.58----Wu et al. \[[@CR31]\]D2DG PG TG19.84 ± 4.718.04 ± 4.14NS6.33 ± 1.916.44 ± 2.040.6215.73 ± 1.475.92 ± 1.110.149Cui et al. \[[@CR30]\]D2PG DG TG29.3 ± 11.830.1 ± 11.40.574----Lu et al. \[[@CR37]\]D2TG18 (17-23)19 (16-24)0.548----Hao et al. \[[@CR33]\]D1,D1+,D2, D2+DG PG TG30.4 ± 13.428.1 ± 17.10.436.15 ± 1.636.09 ± 1.090.545.46 ± 1.745.40 ± 1.950.57Li et al \[[@CR35]\]D2DG33.7 ± 7.133.1 ± 7.60.358----Zhang et al. \[[@CR38]\]D2DG TG17 (16--21)18 (17--25)0.258----Li et al. \[[@CR35]\]D2DG24.7 ± 8.324.6 ± 10.00.9675.8 (5.0, 6.8)5.0 (4.0, 7.5)0.4763.0 (2.0, 3.8)3.0 (2.0, 4.0)0.634Hu et al. \[[@CR34]\]D2DG36.1 ± 16.736.9 ± 16.10.7384.8 ± 2.35.2 ± 2.50.4364.1 ± 2.14.3 ± 2.50.239Zhang et al. \[[@CR40]\]--DG PG TG37 ± 1435 ± 110.05----Xu et al. \[[@CR39]\]D2DG TG6.0 ± 6.96.4 ± 7.20.3534.8 ± 2.54.6 ± 2.40.3546.6 ± 4.27.6 ± 4.70.105Li et al. \[[@CR42]\]D2DG TG------Xu et al. \[[@CR49]\]D2DG TG21.6 ± 8.622.4 ± 10.30.1365.0 ± 2.85.4 ± 2.90.0667.2 ± 4.36.9 ± 4.60.292Inokuchi et al. \[[@CR41]\]D2DG TG39 (14--72)38 (14--89)0.69----Shi et al. \[[@CR44]\]D2PG DG TG31.59 ± 5.8732.18 ± 6.070.377----Park et al. \[[@CR43]\]D2DG37.0 ± 13.439.7 ± 13.30.168----Chan et al. \[[@CR45]\]D2TG37 (7--77)26 (3--95)\< 0.001----Kinoshita et al. \[[@CR46]\]D1, D1+,D2, D2+DG PG TG43 (32--56)34 (24--44)\< 0.001----Wang et al. \[[@CR48]\]D2DG29.5 ± 10.431.4 ± 12.30.0835.0 ± 2.25.3 ± 2.5NS3.8 ± 2.43.9 ± 2.7NSLee et al. \[[@CR47]\]D2DG46.6 ± 17.746.9 ± 15.90.7414.6 ± 3.05.0 ± 3.10.0534.8 ± 3.24.8 ± 3.10.87*NS* not significant, -- not reported, *LN* lymph nodes, *L* laparoscopic, *O* openTable 5Pathological characteristics of included studiesLGOGLGOGLGOGUpperMiddleLowerUpperMiddleLowerT1T2T3T4T1T2T3T4N0N1N2N3aN3bN0N1N2N3aN3bZhang et al. \[[@CR32]\]Zhang et al. \[[@CR40]\]301863352460Zhao et al. \[[@CR18]\]Zhang et al. \[[@CR38]\]102359122654Xu et al. \[[@CR49]\]1851903919711419514837124997195981781591761916411799929626Xu et al. \[[@CR39]\]1311211571511181617Wu et al. \[[@CR31]\]Wang et al. \[[@CR48]\]229181235173584565545235716210043304993433945Shuang et al. \[[@CR17]\]2114221315201322235719115Shinohara et al. \[[@CR27]\]42944626633425966517584873654534449281Shi et al. \[[@CR44]\]35468135398630132351254761351933664021Scatizzi et al. \[[@CR16]\]101591609201092015111461311Qiu et al. \[[@CR29]\]311166721Park et al. \[[@CR43]\]Moisan et al. \[[@CR23]\]127121310815457154572224323243Lu et al. \[[@CR37]\]Lin et al. \[[@CR26]\]241742291143305330533017171929201519Li et al. \[[@CR36]\]Li et al. \[[@CR36]\]621029621029Li et al. \[[@CR42]\]10825299152473231138881001042919017018321994Lee et al. \[[@CR47]\]1401041371321271141371202269690649222103737426Kinoshita et al. \[[@CR46]\]26639543619519026614853147939253374Kim et al. \[[@CR22]\]141856181653442618412324501617546102111Inokuchi et al. \[[@CR41]\]Huang et al. \[[@CR14]\]Hu et al \[[@CR34]\]21487881292167998126Hao et al. \[[@CR33]\]108162358101165313218410196383188134306144135300Hamabe et a. \[[@CR21]\]17282124403721451883Gordon et al. \[[@CR25]\]18488844Fang et al. \[[@CR28]\]2342222539233821171132232210Cui et al. \[[@CR30]\]Chun et al. \[[@CR20]\]39135512339913512128Chen et al. \[[@CR19]\]8114350628142475441252521Chan et al. \[[@CR45]\]2320114847722328359852324307493Cai et al. \[[@CR15]\]24252126Bo et al. \[[@CR24]\]64233065213150674770294246264744*LG* laparoscopic gastrectomy, *OG* open gastrectomy

Operative results {#Sec12}
-----------------

Table [6](#Tab6){ref-type="table"} showed the surgical outcomes of both types of surgery. Twenty-five studies reported the data of intraoperative blood loss \[[@CR15], [@CR16], [@CR19], [@CR21], [@CR22], [@CR25]--[@CR28], [@CR30]--[@CR36], [@CR38], [@CR40], [@CR42], [@CR43], [@CR45]--[@CR47], [@CR49], [@CR50]\], twenty studies demonstrated that LG was significantly associated with less blood loss in the operation \[[@CR15], [@CR19], [@CR20], [@CR22], [@CR25]--[@CR28], [@CR30]--[@CR35], [@CR38], [@CR42], [@CR45], [@CR46], [@CR49], [@CR50]\], and only one study demonstrated the opposite result \[[@CR47]\]. Twenty-nine studies report the data of operative time \[[@CR15]--[@CR17], [@CR19]--[@CR22], [@CR25]--[@CR28], [@CR30]--[@CR36], [@CR38], [@CR40], [@CR42]--[@CR47], [@CR49]--[@CR51]\], the duration of LG was significantly longer than that of OG in twenty-three studies \[[@CR15], [@CR17], [@CR21], [@CR22], [@CR25], [@CR26], [@CR28], [@CR30]--[@CR32], [@CR34]--[@CR38], [@CR40], [@CR42], [@CR44], [@CR45], [@CR47], [@CR49]--[@CR51]\], but only one study demonstrated the opposite result \[[@CR46]\]. Twenty-nine studies report the data of retrieved lymph \[[@CR15]--[@CR17], [@CR19]--[@CR22], [@CR25]--[@CR28], [@CR30]--[@CR36], [@CR38], [@CR40], [@CR42]--[@CR47], [@CR49]--[@CR51]\], twenty-seven have reported the number of retrieved lymph nodes in LG was similar to that in OG \[[@CR15]--[@CR17], [@CR19]--[@CR21], [@CR25]--[@CR28], [@CR30], [@CR31], [@CR33]--[@CR36], [@CR38], [@CR40], [@CR42]--[@CR47], [@CR49]--[@CR51]\], and two studies showed that the number of harvested lymph nodes was significantly higher for LG than OG \[[@CR22], [@CR32]\]. Our analysis showed that LG could produce satisfactory result, which indicated that lymph node dissection could be carried out with laparoscopic surgery (WMD = 0.02, 95% CI = − 0.70, 0.73; *P* \> 0.05; Fig. [2](#Fig2){ref-type="fig"}). Table 6Surgical outcomes of LG and OGReferenceBlood loss (ml)Operating time (min)Harvested lymph nodeLAGOGLAGOGLAGOG2010--2015 Huang et al. \[[@CR14]\]131.91^a^342.3266.05^a^223.7825.8127.47 Cai et al. \[[@CR15]\]293.67344.47270.51187.6622.9822.87 Scatizzi et al. \[[@CR16]\]NANA240^a^1803137 Zhao et al. \[[@CR18]\]128^a^30121120433.232.8 Chen et al. \[[@CR19]\]82.7^a^201.7207.221330.630.3 Chun et al. \[[@CR20]\]NANA207.7^a^159.939.139.3 Hamabe et al. \[[@CR21]\]158.3^a^356.3283.1^a^225.963.7^a^44 Kim et al. \[[@CR22]\]NANA228.3^a^183.638.341.8 Bo et al. \[[@CR24]\]196.9^a^358.2292.8^a^242.135.237.4 Gordon et al. \[[@CR25]\]107^a^495291^a^23535.9236.59 Lin et al. \[[@CR26]\]78.4^a^200.4212.7226.430.228 Shinohara et al. \[[@CR27]\]154.3^a^388.7369.7^a^263.645.343.8 Qiu et al. \[[@CR29]\]120^a^227.3259.5^a^236.0930.228.1 Cui et al. \[[@CR30]\]99^a^125258^a^19429.330.1 Wu et al. \[[@CR31]\]169.46^a^193. 86228.43^a^207.5919.84^a^18.042016--2019 Hao et al. \[[@CR33]\]154.5^a^311.2257.8^a^23130.428.1 Hu et al. \[[@CR34]\]105.5^a^117.3217.3^a^18636.136.9 Li1 et al. \[[@CR35]\]131.9129.5297.4^a^198.133.733.1 Li2 et al. \[[@CR35]\]9497.9214.2^a^200.324.724.6 Lu et al. \[[@CR37]\]250^a^330240^a^1901819 Xu1 et al. \[[@CR39]\]322274326^a^2032425.6 Zhang et al. \[[@CR40]\]143^a^2231892013735 Inokuchi et al. \[[@CR41]\]115^a^420316^a^2423938 Park et al. \[[@CR43]\]NANA257.4^a^1833739.7 Shi et al. \[[@CR44]\]129^a^215.8238.1^a^207.331.5932.18 Xu2 et al. \[[@CR49]\]273.7^a^233.6283.8^a^191.521.622.4 Chan et al. \[[@CR45]\]150^a^275321^a^36539.537.5 Lee et al. \[[@CR47]\]138.3^a^222225.7^a^162.346.646.9 Wang et al. \[[@CR48]\]91.4^a^117.5242.5^a^209.929.531.4*LG* laparoscopy gastrectomy, *OG* open gastrectomy^a^*P* \< 0.05Fig. 2Forest plot of harvested lymph nodes

Considering for this 10-year dramatical surgical material development between 2010 and 2019, we make a subgroup analysis based on published year (2010--2015 and 2016--2019). Thirteen recent studies published between 2016 and 2019 reported intraoperative blood loss \[[@CR34]--[@CR38], [@CR40]--[@CR42], [@CR45]--[@CR47], [@CR49], [@CR50]\], ten studies indicated significantly less intraoperative blood loss in LG \[[@CR34], [@CR35], [@CR38], [@CR41], [@CR42], [@CR45]--[@CR47], [@CR49], [@CR50]\], and no study reported opposite result. Recent fourteen studies reported operative time \[[@CR34]--[@CR38], [@CR40]--[@CR42], [@CR44]--[@CR47], [@CR49], [@CR50]\], and thirteen studies indicated the duration of LG was significantly longer than that of OG \[[@CR34]--[@CR38], [@CR40], [@CR42], [@CR44]--[@CR47], [@CR49], [@CR50]\]. All recent fourteen studies revealed that LG was similar to OG in retrieved lymph nodes \[[@CR34]--[@CR38], [@CR40]--[@CR42], [@CR44]--[@CR47], [@CR49], [@CR50]\], and subgroup analysis focused on 2016--2019 demonstrated no significant difference in lymph node dissection (WMD = − 0.40, 95% CI = − 1.06, 0.26; *P* \> 0.05; Fig. [2](#Fig2){ref-type="fig"}). Furthermore, we make a subgroup analysis based on clinical study type; lymph node dissection showed no significant difference between the two groups in the RCT group (WMD = − 0.69, 95% CI = − 1.45, 0.07; *P* \> 0.05; Figure S[1](#MOESM1){ref-type="media"}) and non-RCT (WMD = 0.39, 95% CI = − 0.55, 1.32; *P* \< 0.05; Figure S[1](#MOESM1){ref-type="media"}). Besides, we make a subgroup analysis based on the type of gastrectomy; similar lymph node dissection was found between the two groups in distal gastrectomy (DG) (WMD = − 0.63, 95% CI = − 1.46, 0.21; *P* \> 0.05; Figure S[2](#MOESM2){ref-type="media"}) and total gastrectomy (TG) (WMD = − 1.22, 95% CI = − 4.70, 2.26; *P* \> 0.05; Figure S[2](#MOESM2){ref-type="media"}).

Postoperative recovery {#Sec13}
----------------------

In terms of postoperative recovery, LG was also superior to OG (Table [7](#Tab7){ref-type="table"}). Twenty-two studies reported a significantly shorter hospital stay after LG than OG \[[@CR15], [@CR17], [@CR19], [@CR20], [@CR25]--[@CR28], [@CR30], [@CR32]--[@CR36], [@CR38], [@CR40], [@CR42], [@CR45], [@CR46], [@CR49]--[@CR51]\]; four studies showed hospital stay in LG was similar to that in OG \[[@CR16], [@CR21], [@CR44], [@CR47]\]. Nineteen demonstrated that first flatus returned earlier after LG with statistical significance \[[@CR15], [@CR17], [@CR19], [@CR20], [@CR26], [@CR27], [@CR30], [@CR32]--[@CR36], [@CR38], [@CR40], [@CR43], [@CR45], [@CR47], [@CR49], [@CR51]\]; six studies showed that first flatus in LG was similar to that in OG \[[@CR16], [@CR21], [@CR25], [@CR42], [@CR44], [@CR50]\]. Seven studies indicated that first out of bed returned earlier after LG with statistical significance \[[@CR19], [@CR25], [@CR28], [@CR30], [@CR34], [@CR35], [@CR45]\]; four studies showed that first out of bed in LG was similar to OG \[[@CR16], [@CR17], [@CR20], [@CR49]\]. Fourteen individual studies reported a significantly earlier first oral intake after LG than OG \[[@CR17], [@CR19], [@CR20], [@CR25], [@CR27], [@CR28], [@CR30], [@CR32], [@CR34]--[@CR36], [@CR42], [@CR45], [@CR49]\]; four studies showed that first oral intake in LG was similar to that in OG \[[@CR15], [@CR16], [@CR43], [@CR50]\]. Table 7Recovery outcomes of LG and OGReferenceHospital stay (days)First flatus (days)First out of bed (days)First oral intakeLAGOGLAGOGLAGOGLAGOG2010-2015 Huang et al. \[[@CR14]\]9.2^a^11.353.18^a^4.5NANA6.537.64 Cai et al. \[[@CR15]\]11.632711.42553.894.21284.77554.89366.85716.4681 Scatizzi et al. \[[@CR16]\]7^a^92^a^3113^a^4 Zhao et al. \[[@CR18]\]7.9^a^10.73^a^3.93^a^4.33.5^a^4.5 Chen et al. \[[@CR19]\]13.3^a^17.42.6^a^3.22.72.94.7^a^5.1 Chun et al. \[[@CR20]\]773.13.1NANANANA Kim et al. \[[@CR22]\]7^a^10.43.2^a^3.7NANANANA Bo et al. \[[@CR24]\]7.4^a^10.73.43.93.1^a^5.34.5^a^5.3 Gordon et al. \[[@CR25]\]8.4^a^18.12.7^a^3.8NANANANA Lin et al. \[[@CR26]\]14.2^a^17.22.9^a^4NANA4.1^a^5.5 Shinohara et al. \[[@CR27]\]16.3^a^24.3NANA2^a^3.23.4^a^5.7 Qiu et al. \[[@CR29]\]13^a^16.92.9^a^4.61.2^a^4.14.5^a^5.5 Wu et al. \[[@CR31]\]9.44^a^11.073.72^a^4.41NANA5.66^a^7.092016--1019 Hao et al. \[[@CR33]\]7.6^a^10.73.3^a^3.93.1^a^4.53.7^a^4.5 Hu et al. \[[@CR34]\]10.8^a^11.31.4^a^3.62.3^a^2.45.5^a^6 Li1 et al. \[[@CR35]\]10.5^a^11.92.8^a^3.6NANA3.8^a^4.6 Li2 et al. \[[@CR35]\]10.87510.6253.2^a^3.9NANA6.3576.25 Lu et al. \[[@CR37]\]8^a^102^a^4NANANANA Xu1 et al. \[[@CR39]\]10.710.24.4^a^4.8NANANANA Zhang et al. \[[@CR40]\]8.6^a^13.22.3^a^3.5NANANANA Inokuchi et al. \[[@CR41]\]9^a^1234NANA2^a^4 Park et al. \[[@CR43]\]9.89.12.62.5NANANANA Shi et al. \[[@CR44]\]7.51^a^10.493.14^a^3.963.15^a^4.373.57^a^4.41 Xu2 et al. \[[@CR49]\]8.2^a^8.74^a^4.4NANANANA Chan et al. \[[@CR45]\]9^a^11NANANANANANA Lee et al. \[[@CR47]\]8.1^a^9.13.53.7NANA3.73.8 Wang et al. \[[@CR48]\]9.9^a^10.92.8^a^3.11.21.47^a^7.9*LG* laparoscopy gastrectomy, *OG* open gastrectomy^a^*P* \< 0.05

In terms of the studies published between 2016 and 2019, eleven studies indicated significantly shorter hospital stay in LG than OG \[[@CR34]--[@CR38], [@CR40]--[@CR42], [@CR44]--[@CR47], [@CR49], [@CR50]\]; three studies reported the similar result between LG and OG \[[@CR37], [@CR40], [@CR44]\]. Compared with OG, the first flatus returned earlier with statistical significance in recent ten studies for LG \[[@CR34]--[@CR38], [@CR40], [@CR41], [@CR45], [@CR47], [@CR49]\], and three studies indicated no significant difference between LG and OG \[[@CR42], [@CR44], [@CR50]\]. Three significant studies showed that first out of bed returned earlier in LG compared with OG \[[@CR34], [@CR35], [@CR45]\], and one study revealed no statistical difference between the two groups \[[@CR49]\]. For the first oral intake, six studies demonstrated a significant result for LG \[[@CR34]--[@CR36], [@CR42], [@CR45], [@CR49]\], and two studies indicated LG was similar to OG \[[@CR37], [@CR50]\].

Postoperative morbidity and mortality {#Sec14}
-------------------------------------

The data from thirty-five studies indicated the rate of overall postoperative complications was lower in LG (RR = 0.84, 95% CI = 0.78, 0.92, *P* \< 0.05) \[[@CR15]--[@CR42], [@CR44]--[@CR49]\]; the result was associated with low-grade heterogeneity between studies (Fig. [3](#Fig3){ref-type="fig"}, Table [8](#Tab8){ref-type="table"}). In terms of the studies published between 2016 and 2019, fifteen studies present data in favor of LG (RR = 0.88, 95% CI = 0.78, 0.99, *P* \< 0.05) \[[@CR34]--[@CR37], [@CR39]--[@CR42], [@CR44]--[@CR47], [@CR49], [@CR50]\]. We furtherly performed a subgroup based on clinical study type, the result favored LG in the non-RCT group (RR = 0.82, 95% CI = 0.74, 0.91, *P* \< 0.05; Figure S[3](#MOESM3){ref-type="media"}), and RCT group indicated that LG has similar postoperative complications to OG (RR = 0.92, 95% CI = 0.77, 1.13, *P* \< 0.05; Figure S[3](#MOESM3){ref-type="media"}). Moreover, we make a subgroup analysis based on the type of gastrectomy; the result of LG was not inferior to OG in TG (RR = 0.77, 95% CI = 0.56, 1.05, *P* \> 0.05; Figure S[4](#MOESM4){ref-type="media"}) and DG (RR = 0.82, 95% CI = 0.68, 1.00, *P* \< 0.05; Figure S[4](#MOESM4){ref-type="media"}). Fig. 3Forest plot of morbidityTable 8Analysis of postoperative morbiditySample sizeHeterogeneity testMeasure outcomesNo. of studiesLGOGOR, WMD, or HRLower 95% CIUpper 95% CI*PI*^2^ (%)*P*Over morbidity357910310.830.770.91\> 0.0514.500.228Specific complications Intra-abdominal bleeding1223280.860.51.47\> 0.0500.838 Anastomotic bleed1214131.140.592.22\> 0.0500.919 Anastomotic stenosis1119240.750.421.31\> 0.0500.747 Anastomotic leakage2475970.850.631.15\> 0.0500.819 Duodenal stump leakage1327290.930.561.52\> 0.0500.845 Abdominal infection1656690.780.551.1\> 0.0500.996 Lymphatic fistula816170.860.451.64\> 0.0500.896General complications Pneumonia201061320.840.651.08\> 0.0500.88 Wound problems22791430.530.410.7\< 0.00013.500.413 Postoperative ileus1535570.640.430.96\< 0.0500.89 Pancreatitis or pancreatic leakage1464421.420.982.05\> 0.0500.935*LG* laparoscopic gastrectomy, *OG* open gastrectomy

The subgroup analysis of postoperative complications showed that significantly lower incidence rate of wound problems (RR = 0.53, 95% CI = 0.41, 0.70; *P* \< 0.05) and postoperative ileus (RR = 0.64, 95% CI = 0.43, 0.96; *P* \< 0.05) in LG group, and there was no significant difference in other surgery complications, including pneumonia, intra-abdominal bleeding, anastomotic bleed, anastomotic stenosis, anastomotic leakage, duodenal stump leakage, abdominal infection, lymphatic fistula, pancreatitis, or pancreatic leakage (Table [8](#Tab8){ref-type="table"}). Ten articles reported the post-operative mortality (RR = 1.27, 95% CI = 0.57, 2.82; *P* \> 0.05) \[[@CR19], [@CR20], [@CR27], [@CR28], [@CR35], [@CR36], [@CR40], [@CR46]--[@CR48]\], with no significant difference and heterogeneity among these included articles (*I*^2^ = 0; *P* = 0.819). There were also no significant difference in post-operative mortality between analyzed groups for recent studies (RR = 1.57, 95% CI = 0.61, 4.05; *P* \> 0.05, Fig. [4](#Fig4){ref-type="fig"}) \[[@CR28], [@CR35], [@CR36], [@CR46], [@CR47], [@CR50]\]. The subgroup analysis based on clinical study type indicated no significant difference in the non-RCT group (RR = 1.05, 95% CI = 0.41, 2.67, *P* \> 0.05; Fig. [5](#Fig5){ref-type="fig"}) and RCT group (RR = 1.05, 95% CI = 0.29, 3.80, *P* \> 0.05; Figure S[5](#MOESM5){ref-type="media"}). The subgroup analysis based on operative procedure also indicated no significant difference in DG (RR = 0.83, 95% CI = 0.19, 3.64, *P* \> 0.05; Figure S[6](#MOESM6){ref-type="media"}) and TG (RR = 1.19, 95% CI = 0.08, 18.50, *P* \> 0.05; Figure S[6](#MOESM6){ref-type="media"}). Fig. 4Forest plot of 30-day mortalityFig. 5Forest plot of 5-year overall survival

Long-term postoperative outcomes {#Sec15}
--------------------------------

Follow-up ranged widely from 1 month to 149.4 months. Sixteen trials contain the data of 5-year overall survival \[[@CR21]--[@CR23], [@CR25], [@CR28], [@CR29], [@CR33], [@CR34], [@CR38]--[@CR42], [@CR46], [@CR47]\]. The results were in favor of the LG group (HR = 0.91, 95% CI = 0.83, 0.98; *P* \< 0.05), with moderate grade between the two groups (*I*^2^ = 65.4%, *P* = 0.999, Fig. [5](#Fig5){ref-type="fig"}). Thirty-five studies reported no significant difference in the over survival rate. The systematic review of long-term outcomes is summarized in Table [9](#Tab9){ref-type="table"}. We furtherly make a subgroup analysis based on published years. As for the studies published in 2010--2015, there was no significant difference in terms of 5-year overall survival (HR = 0.88, 95% CI = 0.71, 1.06; *P* \< 0.05) \[[@CR21]--[@CR23], [@CR25], [@CR28], [@CR29], [@CR33]\]. However, studies published in 2016--2020 revealed LG was associated with better result (HR = 0.90, 95% CI = 0.82, 0.99; *P* \< 0.05) \[[@CR34], [@CR38]--[@CR42], [@CR46], [@CR47]\]. Subgroup analysis based on operative procedure also indicated no significant difference between LG and OG in DG (RR = 0.86, 95% CI = 0.62, 1.10, *P* \> 0.05; Figure S[7](#MOESM7){ref-type="media"}). There was only one study in the TG group, and it also did not report a significant difference (RR = 0.75, 95% CI = 0.18, 1.77; Figure S[7](#MOESM7){ref-type="media"}). Table 9Systematic review of OS outcomesReferencesGroupFollow-up (mo.)OS*P*Zhao et al. \[[@CR18]\]L37 (6--72)1 y, 87.2%; 3 y, 57.2%; 5 y, 50.3%NSO1 y, 87.1%; 3 y, 54.1%; 5 y 49.2%Shuang et al. \[[@CR17]\]L36.5 (23--50)50 mo., 64%NSO38.5 (27--50)50 mo., 60%Scatizzi et al. \[[@CR16]\]L18 (2--37)42 mo., 70.91%0.449O18 (7--42)42 mo., 56.77%Cai et al. \[[@CR15]\]L22.1354 (4--36)40 mo., 67.1%--O40 mo., 53.8%Chun et al. \[[@CR20]\]L60.4 (7.0--91.7)5 y, 91.3%0.613O53.2 (1.0--82.2)5 y, 88.6%Chen et al. \[[@CR19]\]L19 (1--48)1 y, 91.5%0.297O1 y, 89.8%Hamabe et al. \[[@CR21]\]L30.4 (1--60.9)5 y, 94.4%0.4877O53.5 (1.3--111.3)5 y, 78.5%Kim et al. \[[@CR22]\]L53.7 (8.3--138.1)5 y, 85.9 %0.463O58.1 (0.3--106.2)5 y, 83.1%Moisan et al. \[[@CR23]\]L28 mo.3 y, 82.3%0.557O40 mo.3 y, 86.9Gordon et al. \[[@CR25]\]L49.2 (4--146)5 y, 79.2%NSO5 y, 77.2%Bo et al. \[[@CR24]\]L61.2 mo. (6--84 mo.)5 y, 49.3%0.756O5 y, 46.5%Shinohara et al. \[[@CR27]\]L48.8 (25--58.5)5 y, 68.1 %0.968O5 y, 63.7 %Lin et al. \[[@CR26]\]L23.0(12-50 )1 y, 88.0%NSO1 y, 85.5%Fang et al. \[[@CR28]\]L44 (1-82)5 y, 59%5 .525O5 y, 54%Zhang et al. \[[@CR32]\]L385 y, 59%0.523O405 y, 56%Hao et al. \[[@CR33]\]L53.55 y, 57.65%0.22O5 y, 53.69%Li1 et al. \[[@CR35]\]L------O----Zhang et al. \[[@CR38]\]L385 y, 57%0.606O405 y, 50%Zhang et al. \[[@CR40]\]L37 (3--60)1 y, 89.2 %; 3 y, 72.1%; 5 y, 45.7%NSO1 y, 87.4%; 3 y, 68.1%; 5 y, 42.3%Xu et al. \[[@CR39]\]L22(3-100)5 y, 31.3%0.949O5 y, 29.9%Li3 et al. \[[@CR42]\]L69(3--120)5 y, 52.0%0.805O5 y, 53.4%Xu et al. \[[@CR49]\]L58 (0--129)5 y, 51.2%0.081O49.5 (0--104.5)5 y, 46.7%Inokuchi et al. \[[@CR41]\]L62.2 (2.8--149.4)5 y, 70%0.96O62.2 (4.4--130.4)5 y, 73%Park et al. \[[@CR43]\]L38.2----OChan et al. \[[@CR45]\]L2560 mo., 47%0.233O3560 mo., 39%Kinoshita et al. \[[@CR46]\]L3.4 y (1.3--5.0)5 y, 54.2%--O3.5 y (1.7--5.0)5 y, 53.0%*OS* over survival, *DFS* disease-free survival, *NS* not significant, -- not report, *y* year, *mo*. month

No statistical difference was found between the LG and OG groups in tumor recurrence (RR = 0.93, 95% CI = 0.81, 1.07; *P* \> 0.05) \[[@CR19], [@CR21]--[@CR24], [@CR28], [@CR29], [@CR34], [@CR39], [@CR40], [@CR46], [@CR47]\], with moderate-grade heterogeneity (*I*^2^ = 62.2%; *P* = 0.002) (Fig. [6](#Fig6){ref-type="fig"}). Besides, we analyzed the data from studies published in 2016--2019; there showed no significant difference between LG and OG (RR = 0.94, 95% CI = 0.67, 1.31; *P* \> 0.05) \[[@CR19], [@CR21]--[@CR24], [@CR28], [@CR29]\]. Furthermore, subgroup analysis based on operative procedure also indicated no significant difference between LG and OG in DG (RR = 0.94, 95% CI = 0.79, 1.10, *P* \> 0.05; Figure S[8](#MOESM8){ref-type="media"}). There was only one study in the TG group, and it showed lower incidence rate of tumor recurrence in LG (RR = 0.33, 95% CI = 0.14, 0.78; Figure S[8](#MOESM8){ref-type="media"}). In the studies reporting the site of recurrence, local recurrence was the most frequent recurrence site among these common sites; relevant data related with specific recurrent sites are shown in Table [10](#Tab10){ref-type="table"}. Fig. 6Forest plot tumor recurrenceTable 10Systematic review of recurrence pattern and sitesReferenceGroupSizeTotallocalLNLivePeritoneumPort site/woundBoneHematogenousLungAnastomotic stomaGutBrainPancreasMultiple patternOtherZhao et al. \[[@CR18]\]L346147--------------O313141--------------Chun et al. \[[@CR20]\]L526--32----1----O67111513--1----Hamabe et al. \[[@CR21]\]L6650004--0--1--O101211793--1--0--Kim et al. \[[@CR22]\]L88281463--3425O88234341--0722Moisan et al. \[[@CR23]\]L315--------------5O314--------------4Bo et al. \[[@CR24]\]L11723----415--1--3O11726----220------4Shinohara et al. \[[@CR27]\]L186851515--29----23--O123541111--17----15--Fang et al. \[[@CR28]\]L8736----------------O8745----------------Lu et al. \[[@CR37]\]L611973--60--3--O612083--70--2--Hao et al. \[[@CR33]\]L6281961220--45----30--O579158911--42----23--Zhang et al. \[[@CR38]\]L9228235941--13O92322251071--14Xu et al. \[[@CR39]\]L6749----------------O6760----------------Li3 et al. \[[@CR42]\]L4101154410--51----2517O4101015113--49----2023Xu et al. \[[@CR49]\]L43020397--426212--16109215O768387175--7712024--2633167512Chan et al. \[[@CR45]\]L545----------------O16747----------------Kinoshita et al. \[[@CR46]\]L2611003212042--4--46O2581214322245--3--510*NS* not significant, -- not reported, *LN* lymph nodes, *L* laparoscopic, *O* open

Discussion {#Sec16}
==========

Between 2010 and 2019, there are many high-quality RCTs that have been published. However, many previous meta-analyses have included low-quality studies or a limited number of studies \[[@CR52], [@CR53]\]. Thus, we conducted the meta-analysis to evaluate whether LG is an alternative treatment for AGC. Some primary endpoints were compared between LG and OG, including intraoperative time, intraoperative blood loss, harvested lymph nodes, proximal and distal resection margin distance, time to first flatus, time to first oral intake, post-operative hospital stay, complication and mortality, rate of disease recurrence, and 5-year over survival.

The LG consumed significantly more time than OG, although we could get a wider operation field by applying LG. However, the operative process is more complicated and less flexible than OG; some reasons include the narrow operating field, restriction in the number of trocar \[[@CR54]\], lacking of tactile sensation \[[@CR55]\], insufficient training \[[@CR56]\], the time for setting up the equipment, and the complexity of performing the esophagojejunostomy \[[@CR57]\], while LG combined with advanced techniques for systemic lymphadenectomy may be the main reason, which needs experienced surgeons. In terms of AGC, compared with gastrectomy alone, gastrectomy combined with systemic lymphadenectomy is more complicated. Meanwhile, compared with other laparoscopic surgery including laparoscopic colectomy and cholecystectomy, LG with lymphadenectomy is also more difficult because it is necessary to identified many important vessels and clear lymph node. Recently, some studies have indicated that the operative time could significantly reduce and reach a plateau after about 40 cases, and the operative time of LG is no longer than OG for extensive technical expertise \[[@CR51], [@CR58], [@CR59]\]; meantime, some high-quality studies reported postoperative morbidity has no significant difference between LG and OG, with LG leading to faster postoperative recovery \[[@CR60]\]. With the development and improvement of laparoscopic techniques, the operative time will reduce and become shorter.

In spite of the operative time is longer, blood loss is significantly less in LG. For LG, by using the laparoscopic device such as ligatures and ultrasonic scalpel, we could get enlarged surgical vision to detect large and small vessels and expose vessel adequately, which contribute to small blood loss. The small amount of blood loss may contribute to a decreased blood transfusions, which could reduce the postoperative complication such as lung injury, volume overload, and pneumonia. Thus, small amount of blood loss has an impact on postoperative recovery and recurrence \[[@CR61]\].

The postoperative complication is usually used to evaluate the surgical safety. The meta-analysis demonstrated that the overall postoperative complication rate of LG was significantly lower than OG; meantime, the wound problem and postoperative ileus were significantly less common than OG, which is in consistent with some previous meta-analysis \[[@CR62], [@CR63]\]. For LG, the smaller surgical surface wound and less manual handling may account for less wound problem, and LG could reduce the intervention to microenvironment of abdominal cavity and intestinal serous membrane, which may decrease the rate of postoperative ileus. The rate of postoperative pneumonia was lower than OG with no significant difference. In terms of OG, some disadvantages may make it difficult to cough, which lead to respiratory complications such as pneumonia, including tension sutures, serious pain, and abdominal bandages, while patients in LG were related with less blood loss, less blood transfusion during surgery \[[@CR64], [@CR65]\], and less wound pain after surgery \[[@CR66]\]. For other postoperative complications including pancreatitis/pancreatic leakage, intra-abdominal bleeding, anastomotic bleeding, anastomotic stenosis, anastomotic leakage, duodenal stump leakage, abdominal infection, and lymphatic fistula, there were no significant differences.

With regard to the time to first flatus, the time to first oral intake, and post-operative hospital stay, the results were favoring for LG. LG is thought to be a less invasive procedure with smaller surgical incision and minimal gastrointestinal interference, so that the postoperative pain is less during recovery with a reduced inflammatory response and better glucose tolerance \[[@CR67], [@CR68]\], which has a direct impact on a quick recovery of bowel function, and a quick recovery represents earlier oral intake, earlier discharge, and shorter hospital stay. In other words, it is quicker to return to normal condition in LADG than ODG. The cost of laparoscopic surgery is higher for LG compared with OG, because of the costs of the disposable instruments, while Miura et al. \[[@CR69]\] indicated that LADG was less expensive than ODG because hospital stay is shorter and additional costs can be offset by the lower charges for ward, meals, and nursing care.

In terms of oncological safety, in most previous studies, the number of HLNs is widely considered as the index of "quality" \[[@CR70]--[@CR75]\]; adequate LN dissection could reduce the possibility of recurrence and metastasis. The efficiency for lymphadenectomy is still the main concern; the efficiency represents surgical removal of fifteen lymph nodes is the minimum standard. In most previous studies and our present studies, the mean number of harvested lymph nodes was more than fifteen for LG. However, whether laparoscopy could reach the same result as open surgery is still controversial; a previous study showed that experienced surgeons could realize the radicality in lymphadenectomy if the operative time is not limited \[[@CR76]\]. In the present meta-analysis, we discovered that the harvested lymph nodes have no significant difference, which indicated LG could retrieve as many LNs as did OG through the improvement in laparoscopy facilities and sufficient training. D1+α or β dissection is now adequate for selected patients with early gastric cancer. With regard to advanced gastric cancer, whether D2 dissection is superior to D1 dissection remains controversial \[[@CR77], [@CR78]\]. D2 dissection could realize more radical lymphadenectomy than D1 dissection, whereas D2 dissection could increase the postoperative mobility and mortality because of the invasiveness. In East Asia, maybe the incidence is high so that Asian surgeons are familiar with gastric cancer and have a better understanding of surgical technique; D2 lymphadenectomy is generally accepted as the standard to treat AGC. The Japanese Gastric Cancer Association has presented D2 lymphadenectomy as the standard treatment of local AGC \[[@CR79]\]. However, some western studies have reported no significant long-term advantage with higher operative morbidity and mortality rates after D2 lymphadenectomy \[[@CR80]--[@CR82]\], and western surgeons would like to perform D1 lymphadenectomy; many recent report have indicated that patients who underwent laparoscopic gastrectomy combined with systemic lymphadenectomy could get a good survival result by extensively trained western surgeons \[[@CR83], [@CR84]\]. Therefore, insufficient training of the laparoscopic gastrectomy combined with systemic lymphadenectomy may be the main reason for western surgeons. D2 dissection is an appropriate treatment for patients with advanced disease. Proximal esophageal and distal duodenal margins is also used to assess oncological adequacy, and proximal and distal margin distance could reflect the radicality of surgery, which is related with recurrence and OS and DFS in GC and other cancer \[[@CR85]\]. Meantime, surgical margin is considered as an independent prognostic factor for GC. Our analyses also showed that there was no significant difference between the two groups; it indicated that LG is oncologically acceptable for proximal or distal located tumors.

Long-term outcome is the most useful endpoint to evaluate the oncological safety and effectiveness of surgery. Tumor recurrence and 5-year OS are usually used to evaluated the long-term outcome. Many studies have showed tumor recurrence was similar between the LADG and ODG \[[@CR86], [@CR87]\]; previous clinical studies and meta-analysis have revealed that there was no significant difference in the 5-year OS between LADG and ODG \[89\]. In our meta-analysis, we make subgroup analysis based on published year; there demonstrated no statistically significant difference between the two groups; however, the results of 5-year OS favor LG with significant difference between 2016 and 2020, and the tumor recurrence showed no significant difference between the two groups. In other words, at least, LG is not inferior to ODG in terms of oncologic outcomes, which is acceptable for treatment of AGC.

Some limitations exist that should not be neglected for this meta-analysis. Many studies related with the theme are non-randomized retrospective trials; therefore, we have analyzed both the RCTs and NRCTs to avoid lack of samples. Several drawbacks of methodology may lead to heterogeneity, although the study has no observed obvious heterogeneity. In many included studies, the patients with multiple tumor stages were incorporated into one group and included in a single survival curve; it will have a significant effect on the quality and results of the meta-analysis. More ongoing RCTs should be performed to resolve the problem in the future.

Conclusion {#Sec17}
==========

In conclusion, we make a systematic review of thirty-six studies to release LG could be considered to be expanded in treating AGC. Gastric cancer is difficult to diagnose early with a poor prognosis, and patients often do not realize until cancer progresses to middle and advanced stages. Our study has presented the safety and curability of LG, which indicated an encouraging result for LG to be widely accepted in the future. More ongoing RCTs comparing the LAG with OG should be recommended.
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LG

:   Laparoscopic gastrectomy

OG

:   Open gastrectomy

AGC

:   Advanced gastric cancer

5-y OS

:   5-Year over survival

RCT

:   Randomized controlled trials

NRCT

:   Retrospective studies

NOS

:   Newcastle-Ottawa Quality Assessment Scale

JCS

:   Jadad scale

RR

:   Relative risks

WMD

:   Weighted mean differences

HR

:   Hazard ratios

DG

:   Distal gastrectomy

TG

:   Total gastrectomy
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